Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
- Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation
Paris, June 29, 2023. - Today Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team.
- Global Head of Vaccines R&D, Sanofi
“With the addition of mRNA, we now have the largest development toolbox in the industry. - Adding machine learning and antigen design means that our future vaccines will raise the bar beyond today’s high standards.